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Summary In this review we shall discuss the biological rationale and the clinical findings obtained using
Interleukin 2 (IL2)-based immunotherapy in the management of cancer patients. Objective and long-lived
clinical responses have been documented in a proportion of cases, particularly renal cell carcinoma, melanoma
and acute myeloid leukaemia. Though encouraging, the clinical use of IL2 has so far been limited by toxicity,
as well as by the heterogeneous and unpredictable responses and by the lack of specific anti-tumour effect.
These considerations have led to the belief that more sophisticated technologies aimed at introducing the IL2
gene into the neoplastic cells may potentially overcome some of the limitations coupled to the in vivo infusion
of high doses of IL2. The data accumulated in animal models and, more recently, also with human tumour
cells indicate that the IL2 gene may be successfully inserted into neoplastic cells. The constitutive secretion of
IL2 by the tumour cells leads to a reduced or abrogated tumorigenicity in several different tumour models.
The evidence that in some experimental tumours the transduction of the IL2 gene into the neoplastic cells may
elicit a specific cytotoxic response and confer anti-tumour memory, suggests that vaccination protocols based
on this innovative strategy may represent a potential new tool in the management of cancer patients.
These last few years have witnessed a new wave of excitement
in the advocates that biological treatment, if adequately plan-
ned, may have a role in the management of patients with
cancer. In addition to the documented efficacy of alpha
Interferon (IFN) in different neoplastic conditions (Goldstein
& Laszlo, 1986), particularly hairy cell leukaemia and
chronic myeloid leukaemia, this has largely been contributed
by the use in clinical practice of Interleukin 2 (IL2)-based
immunotherapeutic protocols. This innovative therapeutic
modality stems from the recognition that IL2-first described
in the mid seventies as T-cell growth factor (TCGF) because
of its proliferative effect on normal T-lymphocytes (Morgan
et al., 1976)-is a cytokine with a highly pleiotropic activity
(for a review see Smith, 1988). In the context of potential
control of tumour growth, IL2 is capable of boosting the
natural killer (NK) compartment, augmenting the cytotox-
icity of human monocytes, inducing T-helper function and
increasing the reactivity of previously generated cytotoxic
T-lymphocytes (CTL) (Ortaldo et al., 1984; Erard et al.,
1985; Forni et al., 1988). Most relevantly, in the early eighties
it was shown that following incubation with IL2, normal
peripheral blood lymphocytes revealed a previously unrecog-
nised cytotoxic activity mediated by the so-called LAK (lym-
phokine activated killer) effectors (Grimm et al., 1982). Char-
acteristically, these non-MHC (major histocompatibility
complex)-restricted effectors are capable of lysing NK-
resistant tumour cells, whilst showing a lower degree of
toxicity towards normal cells. The studies carried out in
experimental models have convincingly shown that the
infusion of IL2, either alone or in combination with ex-vivo
generated LAK cells, is capable of displaying an anti-
neoplastic effect which can abrogate or delay the growth of
established pulmonary and liver metastases in different
tumour models (Mule' et al., 1984; Lafraniere & Rosenberg,
1985). More effective responses have been recorded by com-
bining IL2 with tumour infiltrating lymphocytes (TIL) rather
than with LAK cells (Rosenberg et al., 1986; Rosenberg,
1991), suggesting that lymphocytes with selective killing
capacity may infiltrate the tumour site possibly through a
mechanism of specific tumour associated antigen (TAA)
recognition. These effector cells appear to be MHC-restricted
and their action can be blocked by monoclonal antibodies
against MHC class I antigens.
These pre-clinical observations opened the way to the
numerous clinical studies which have assessed first the
feasibility of employing IL2, with or without LAK/TIL cells,
in the management of patients with cancer, and thereafter the
potential anti-neoplastic efficacy of this novel therapeutic
strategy.
IL2 in the management of cancer patients
The clinical studies carried out have demonstrated for the
first time that in a proportion of cancer patients with
advanced disease and resistant to conventional treatment, a
pure immunological approach based on the administration of
high doses of IL2, with or without ex-vivo generated LAK or
TIL cells, could induce clinically documentable regressions
(Rosenberg et al., 1985; 1987; 1988; West et al., 1987; Parkin-
son et al., 1990). Based on the earlier clinical findings and on
an extensive review of 652 patients treated (Rosenberg et al.,
1989), the most favourable results have been consistently
documented in metastatic renal cell cancer and melanoma, in
which complete or, more frequently, partial responses in the
order of about 20% are to be expected. Some of these
responses may be long-lived. Of 18 complete responders
reported by Rosenberg et al. (1989), ten were in persistent
complete remission between 18 and 52 months from treat-
ment. A higher therapeutic efficacy has been recently sug-
gested in renal cell carcinoma patients 'induced' with IL2
plus LAK cells and 'maintained' with a more prolonged
period of low-dose daily IL2 administration (Thompson et
al., 1992). Overall better responses have been reported in
advanced melanoma using IL2 and TIL (Rosenberg, 1991);
interestingly, objective responses could be documented also in
patients who were resistant to IL2 alone. These results
appear conceivable in light of the evidence that specific
cytotoxic T-lymphocytes (CTL) directed against the
autologous tumour cell population have been documented in
human metastatic melanoma (De Vries & Spits, 1984;
Anichini et al., 1985). In addition, melanoma is the tumour
in which CTLs have been used to define and clone the first
TAA in human cancer (Van Der Bruggen et al., 1991).
More recently, it has been suggested that IL2 may also
play a role in the management of acute leukaemia patients.
Its use in vivo had necessarily to be preceded by careful
pre-clinical investigations, which, in essence, demonstrated
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that acute leukaemia blasts can be lysed by LAK effectors
and that the growth in immunosuppressed nude mice of
human leukaemic cells can be blocked by normal LAK
effectors of by IL2 alone (Dawson et al., 1986; Oshimi et al.,
1986; Lotzova et al., 1987; Fierro et al., 1988; Adler et al.,
1988; Lista et al., 1989; Foa et al., 1990a). Furthermore, data
accumulated from in vitro and in vivo nude mice experiments
indicate the unlikelihood that leukaemic blasts may pro-
liferate to a significant degree in the presence of IL2 (Foa et
al., 1990a). The clinical studies started more than 4 years ago
have documented the feasibility ofadministering recombinant
IL2 to patients with acute leukaemia, both in terms of doses
which may be infused and of overall toxicity (Foa et al.,
1989, 1990b, 1991a; Maraninchi et al., 1991; Lim et al.,
1992). Furthermore, they have suggested that IL2 may dis-
play an anti-leukaemic effect, particularly in acute myeloid
leukaemia patients with a limited proportion of detectable
resistant blasts (Foa et al., 1990b, 1991a; Lim et al., 1992). In
this clinical situation complete and prolonged remissions
have been obtained with repeated cycles of IL2 alone (Foa et
al., 1990b, 1991a; Lim et al., 1992).
Pilot studies have also shown the feasibility of administer-
ing IL2 to acute leukaemia patients who have undergone an
autologous bone marrow transplant (Blaise et al., 1990;
Higuchi et al., 1991; Soiffer et al., 1992; Meloni et al., 1992).
These findings suggest the potential use of IL2 after engraft-
ment to boost the immune system of the host in an attempt
to control or reduce/eradicate minimal residual disease fol-
lowing maximum cytoreductive treatment. This approach
gains further strength by the possibility that endogenous and
IL2-responsive LAK precursor cells may be detected in the
circulation early after an autotransplant (Reittie et al., 1989;
Higuchi et al., 1989). In view of the progressively growing
use of bone marrow and peripheral blood stem cell autograf-
ting procedures in solid tumours, it is foreseeable that the
application of this immunotherapeutic approach in the man-
agement of cancer patients will expand in the next few years.
The likelihood that the anti-neoplastic effect observed in
solid tumours and in acute leukaemia patients may be
mediated by the immune system of the host activated by the
IL2 administered, is documented by the multiple mor-
phological, phenotypic and functional modifications observed
in the treated patients. On haematological grounds, each
cycle of IL2 is followed by a more or less evident absolute
lymphocytes, characterised in particular by a marked increase
in large granular lymphocytes, which physiologically com-
prise cytotoxic effectors. The immunological changes may be
summarised by the expression of activation markers, as well
as by the amplification of the NK and LAK functions and by
the in vivo release of two cytokines-IFN gamma and
Tumour Necrosis Factor (TNFa)-with known anti-prolifer-
ative activity (Sondel et al., 1988; Hank et al., 1988; Gottlieb
et al., 1989; Heslop et al., 1989; Foa et al., 1991b). Table I
describes the main immunological modifications induced in
cancer patients treated with IL2-based immunotherapy. It is
worth noting that in acute leukaemia patients the generation
of endogenous LAK cells, i.e. activated in vivo by the IL2
administered, has been documented both in the blood and in
the bone marrow (Foa et al., 1991b). A higher proportion of
endogenous LAK effectors could be demonstrated when IL2
was given after a bone marrow autograft (Meloni et al.,
1992), confirming the presence of cytotoxic precursors in this
well defined clinical setting.
Despite these potentially promising results, the overall app-
lication of this innovative approach to the management of
cancer patients has been rather limited. In particular, no
randomised study has so far assessed the effectiveness of IL2
in solid tumour patients with limited or minimal residual
disease, setting in which IL2-based immunotherapy should
have a better chance ofproving to be effective. This is largely
to be ascribed to the toxicities, frequently very severe,
associated with the administration of potentially therapeutic
doses of IL2. In view of the short half-life of IL2, high doses
are in fact employed in patients with active disease in an
attempt to generate an anti-tumour effect. Side effects have
been particularly worrying when high doses of IL2 have been
administered by bolus infusion to patients with poor perfor-
mance status. This has led to alternative modalities of IL2
administration which include continuous infusion protocols
(West et al., 1987), continuous infusion protocols using a
daily dose escalating scheme (Foa et al., 1990b; 1991a), pro-
longed low-dose daily infusion (Caligiuri et al., 1991), as well
as loco-regional injections of IL2 directly in the tumour area
or around tumour-draining lymphnodes (Cortesina et al.,
1988). In experimental models, this latter approach has been
shown to inhibit tumour growth via the triggering of non-
reactive lymphocytes (Forni et al., 1985).
Another limiting factor towards the realisation of ran-
domised studies with IL2 in earlier disease patients is
represented by the heterogeneous and, so far, unpredictable
responses observed. This would require a high number of
patients enrolled, and, in view of the kinetics of solid
tumours, a long clinical follow-up in order to determine
whether IL2 may be truly beneficial for early disease patients.
Finally, while in all patients treated with IL2 a marked
activation of the cytotoxic compartment of the host can be
documented, the latter has so far not correlated with the
clinical response to IL2 (Favrot et al., 1990; Foa et al.,
1991b); furthermore, no evidence has been accumulated that
cytotoxic effectors specifically poised against the autologous
tumour can in fact be generated in vivo. The lack of correla-
tion between clinical response and various 'activation
markers' extends beyond the immune system of the host and
applies also to other clinico-haematological parameters, e.g.
hepato-splenomegaly, WBC count, lymphocytosis, etc.
The recent development of more sophisticated technologies
has offered new and potentially more effective approaches to
biological therapy. In addition to opening innovative
therapeutic avenues, they could help to overcome at least
some of the limitations related to the in vivo administration
of high doses of IL2. In particular, it has recently been
shown that cytokine, including IL2, and growth factor genes
can be successfully and stabily inserted into tumour cells.
Using these gene transduction technologies it could be dem-
onstrated that, through different mechanisms, the tumor-
igenicity of several tumours may be blocked or reduced
following the insertion and expression of several cytokine
genes (see below).
Cytokine and growth factor gene transduction into tumour cells
Table I Main modifications of the immune system ofcancer patients
treated with 1L2-based immunotherapy
* EXPRESSION OF ACTIVATION MARKERS ON HOST
LYMPHOCYTES (CD25/TAC, DR)
* AMPLIFICATION OF LYMPHOCYTES EXPRESSING A
CYTOTOXIC PHENOTYPE (CD16, CD56 ANTIGENS)
* ENHANCEMENT/IMPROVEMENT OF THE NK
FUNCTIONa
* INCREASE IN IL2-INDUCED LAK ACTIVITYa
* GENERATION OF ENDOGENOUS LAK EFFECTORSa * IN VIVO RELEASE OF TNF ALPHA AND IFN GAMMA
aln acute leukaemia patients these modifications have been shown to
occur also in bone marrow lymphocytes
Different techniques have been employed in an attempt to
introduce genes into mammalian cells. Because of their
higher efficiency rates, retroviral vectors, which enable a
stable integration of the given gene into the genome of the
host cell population and the expression of the encoded pro-
tein, have been the preferred method for gene transfer (Gil-
boa et al., 1986; Eglitis & Anderson, 1988; McLachlin et al.,
1990). Using retroviral vectors, it has been possible to intro-
duce genes for several cytokines and growth factors into
different neoplastic cells. In addition to IL2, which will be
discussed in detail below, the transfer of genes coding for
IL4, IL5, IL6, IL7, IFN gamma, TNF alpha and G-CSF into
murine tumour cells has been successfully accomplished.994 R. FOA et al.
More relevantly, the constitutive release of IL4 (Tepper et al.,
1989; Golumbek et al., 1991), IL6 (Porgador et al., 1992),
IL7 (Hock et al., 1991), IFN gamma (Watanabe et al., 1989;
Gansbacher et al., 1990a), TNF alpha (Blankenstein et al.,
1991; Asher et al., 1991) and G-CSF (Colombo et al., 1991)
by the genetically engineered tumour cells has resulted in a
decreased or abrogated tumorigenicity. The mechanisms by
which this anti-tumour response, induced by the release of
the different cytokines and growth factors, is obtained is
most likely heterogeneous, including in some models local
intra-tumoural inflammation and in others the generation of
cytotoxic T-lymphocytes. The analysis of the complex and
only partly understood mechanisms underlying this remark-
able anti-tumour effect elicited by the 'manipulation' of the
immune system of the host following transduction of
cytokine/growth factor genes other than IL2 goes beyond the
scopes of this review.
IL2-gene transfer into tumour cells
Conceptually, the productive insertion of the IL2 gene into
tumour cells should help to circumvent two of the key limita-
tions associated with the in vivo administration of IL2, i.e. (1)
the relevant side effects experienced in all patients with the
high doses of IL2 required to elicit an anti-tumour effect, and
(2) the lacking demonstration that the infusion of IL2 can
induce the generation of a specific killing machinery. The
expected goal is that the in vivo infusion of tumour cells
transduced with the IL2 gene will allow the constitutive
release of amounts of IL2 too low to produce significant side
effects to the patient, but sufficient to generate an anti-
tumour response via the immune system of the host. This
should become apparent through the amplification of the NK
compartment, the generation of LAK effectors and the local
release of TNF alpha and IFN gamma. In addition, the
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presence or putative presence of TAA on tumour cells -at
the site of IL2 release-may trigger the activation of specific
CTL. These could then recirculate and reach the potential
sites of residual neoplastic disease. A cartoon illustrating the
potential use of IL2 gene transfer technologies in the man-
agement of cancer patients is shown in Figure 1. A further
goal of this innovative approach-clearly not limited to the
insertion of the IL2 gene-is that of eliciting an anti-tumour
immunological memory within the T-lymphocytes of the
host.
The data so far accumulated support the above described
theoretical considerations. The insertion of the IL2 cDNA
has in fact been successfully accomplished in several murine
tumours and this is coupled to the constitutive secretion of
variable amounts of IL2 and to the generation of an anti-
tumour response. Fearon et al. (1990) demonstrated that the
injection in BALB/c mice of the weakly immunogenic CT26
murine colon cancer cells engineered to release IL2 was
capable of generating an MHC class-I restricted CTL res-
ponse against the parental tumour, mediated by CD8-positive
cells. Furthermore, in the mice challenged with the IL2 trans-
duced CT26 cells tumour growth could no longer be
detected. The authors showed that the anti-tumour effect was
due to CD8-positive CTLs and that it occurred also in the
absence of CD4-positive T-cells, indicating that transduction
of the IL2 gene could bypass T-cell helper requirement in the
generation of an anti-tumour response. Finally, a protective
immunity against further challenge by the parental, non-
transduced cells could be documented. A similar evidence of
inhibition of tumour growth, generation of a specific T-cell
mediated cytotoxicity and durable anti-tumour memory has
also been observed with the poorly immunogenic CMS5
fibrosarcoma cell line (Gansbacher et al., 1990b). A reduction
in the tumorigenic potential of a transplantable rat sarcoma
infected with an IL2 cDNA has also been reported (Russell
et al., 1991); furthermore, we have shown that in the murine
B-lymphoma 38C13, following retroviral-mediated transfer of
Figure 1 Cartoon illustrating the rationale for transducing the IL2 gene into tumour cells. APC = Antigen Presenting Cell;
NK = Natural Killer; LAK = Lymphokine Activated Killer; CTL = Cytotoxic T-lymphocyte.IL2 AND IL2 GENE THERAPY FOR CANCER 995
the IL2 gene, the transduced tumour cells showed a
diminished in vivo growing capacity (Gansbacher et al.,
1991).
While the results so far discussed with the IL2 gene-as
well as those obtained with other cytokine and growth factor
genes-refer entirely to animal models, recent data indicate
that similar conclusions may be drawn also for human neo-
plastic cells transduced with the IL2 gene. Using retroviral
vectors, a successful insertion of the IL2 gene and effective
production of the cytokine has been accomplished in human
renal cancer and melanoma cell lines (Gastl et al., 1992;
Gansbacher et al., 1992). Tumour formation in nude mice by
the IL2-producing melanoma and renal cell carcinoma cells
was abrogated, compared to the parental unmodified lines.
Furthermore, the production of IL2 was maintained for
several weeks, also following irradiation of the tumour cells
with doses capable of inhibiting their proliferation. Recent
unpublished data also suggest that in an autologous system
IL2-transduced melanoma cells may induce the generation of
specific CTL by the patients own lymphocytes (Guarini et al.,
in preparation).
As a natural continuation of the clinical studies on the
possible role of IL2 in the management of acute leukaemia
patients and of the ongoing project on the 38C13 murine
lymphoblastic lymphoma (Gansbacher et al., 1991), we have
also attempted to transfer the IL2 gene into human
leukaemic cells. The results so far obtained indicate that
using retroviral vectors human acute leukaemia cells can be
transduced with the IL2 gene and induced to secrete IL2
constitutively. The tumour growth potential of the IL2-
infected cells in immunosuppressed nude mice is markedly
retarded or abrogated compared to that of the parental cell
line or of the cell line infected with an irrelevant gene (in
preparation). Attempts are being made to generate killer cells
specifically directed against the IL2-transduced leukaemic cell
population.
Though the IL2 gene may be effectively inserted into the
cells of different animal and human tumours, the amounts of
IL2 released/106 cells can vary considerably. This is shown by
the representative examples of IL2-transduced murine and
human tumours reported in Table II. It is, however, worth
noting that a decreased or abolished tumorigenicity can be
documented even with low levels of IL2 secreted. In order to
obtain subclones of the bulk population capable of releasing
higher quantities of IL2, the tumour cell lines can be cloned
in semisolid medium or by limiting dilution. This procedure
will, however, lead to the loss of the heterogeneous
phenotipic representation of the primary tumour cell popula-
tion which is likely to play an important role in the potential
therapeutic exploitment of gene transfer technoligies.
Conclusions and perspectives
The results so far obtained in experimental models and, more
recently, also with human neoplastic cells, suggest that trans-
fer of cytokine/growth factor genes into neoplastic cells is no
longer only a theoretical consideration, but rather it
represents a reality which opens potential new prospects in
Table II IL2 production by different murine and human tumour cell
lines transduced with the IL2 gene
IL2 released
Source of cells (U/l x 106 cells)F
Fibrosarcoma (CMS5) 61
Murine lines
lB-Lymphoma (38C13) I I
Leukaemia (4) 0.6 9a
Human lines Melanoma (6) 1-80a
(No. lines
tested) Renal Cell (7) 4_72a
aRange of IL2 secretion from the different lines.
the management of cancer patients. Restricting our discus-
sion to IL2, the topic of this review, the murine tumour
model findings clearly document that the tumorigenicity of
poorly immunogenic tumours can be decreased or abrogated
following insertion of the IL2 gene and constitutive secretion
of the cytokine. Evidence has also been provided that the
anti-tumour process is mediated by the immune system and
that gene transfer may, at least in some tumours, confer an
immunological memory.
The most recent findings with human tumour cells seem to
point in the same direction. In addition to demonstrating
that the tumour growth potential of renal cancer, melanoma
and acute leukaemia cells in mice can be inhibited following
IL2 gene transfer, they have also shown that following
irradiation with 5,000 or 10,000 rad the growth of cytokine-
releasing tumour cells is inhibited, whilst their capacity to
secrete IL2 is still maintained for several weeks. This is
important in view of the potential clinical use of vaccination
protocols based on the in vivo injection of genetically
engineered irradiated neoplastic cells. The recent suggestion
that also with human melanoma cells the transduction of the
IL2 gene may lead to the generation of a specific recognition
of the autologous tumour, further fulfills one of the pre-
clinical desires of gene transfer studies. Thus, through the
murine tumour models and the human tumour data so far
accumulated some of the most desired goals of an optimal
immunotherapeutic approach-i.e. (a) the local release of low
doses of IL2 capable of activating the immune system of the
host, (b) the activation of cytotoxic cells specifically directed
against the autologous tumour, and (c) the generation of an
immunological memory-seem to have been, at least in part,
accomplished. Table III shows the scenario of IL2 gene
transfer from the early step of gene insertion to the potential
acquisition of an anti-tumour memory.
Taken together, the data available suggest that immuno-
therapy for cancer patients, in addition to the use of
exogenously administered biological response modifiers and
to the adoptive transfer of ex-vivo activated cells, may in the
near future rely on a new tool based on the direct genetic
engineering of neoplastic cells and insertion of the IL2 gene,
which, in turn, can elicit an in vivo anti-tumour response
mediated by the immune system of the host. Based on the
pre-clinical findings so far accumulated, this novel approach
seems potentially feasible in the three tumours-renal cell
carcinoma, malignant melanoma and acute leukaemia-for
which treatment with IL2/LAK cells has yielded some of the
most promising clinical results. These considerations justify
the attempts, underway or about to be started in melanoma
and renal cell carcinoma, to carry out vaccination protocols
aimed at the use in vivo of tumour cells transduced with the
IL2 gene. The goal is to perform repeated injections of
genetically engineered irradiated tumour cell lines which no
longer proliferate, but are still capable of releasing con-
stitutively IL2. The protocols recently approved at the
Memorial Sloan-Kettering Cancer Center of New York con-
template using IL2-transduced HLA A2+ irradiated tumour
cell lines. Since 40% of the Caucasian patients is HLA A2+,
a large proportion of the patient population is potentially
eligible for this novel strategy. The likelihood that the IL2
Table III Scenario of IL2 gene transfer into tumour cells
1. CONSTRUCTION OF A RECOMBINANT IL2
GENE-CARRYING VECTOR
2. INFECTION OF TUMOUR CELLS WITH INTEGRATION
OF THE PROVIRUS INTO THE HOST CHROMOSOMES
3. CHARACTERISATION OF CONSTITUTIVE IL2
EXPRESSION AND RELEASE BY TRANSDUCED
TUMOUR CELLS
4. INJECTION OF CHARACTERISED 1L2-TRANSDUCED
TUMOUR CELLS INTO THE HOST
5. AMPLIFICATION OR GENERATION OF NK, LAK AND
CTL EFFECTORS
6. REDUCED OR ABROGATED TUMORIGENICITY
7. GENERATION OF ANTI-TUMOUR MEMORY996 R. FOA et al.
released by the injected cells may elicit an anti-tumour
immune response possibly contributed by the generation of
cytotoxic cells specifically directed against the tumour, gains
further strength by the recent evidence that in the peripheral
blood of melanoma patients specific anti-tumour cytotoxic
lymphocyte precursors have been described (Coulie et al.,
1992). It is conceivable that these cytotoxic cells may be
amplified in vivo following repeated boosting with IL2-gene
transduced tumour cells. The possibility that this may occur
gains strength by the evidence that in the P815 mastocytoma-
bearing mice the number of tumour-specific CTL could be
increased following immunisation with IL2-producing tumour
cells (Ley et al., 1991). Hopefully, these cytotoxic effectors
would then recirculate and reach the sites of residual disease,
and, potentially, confer an anti-tumour immunological
memory.
Necessarily, the early clinical applications will have to be
through phase I studies aimed at assessing the feasibility and
safety of this new approach. It is, however, likely that this
innovative therapeutic modality will find a more suitable and
potentially fruitful use in the setting of patients with limited
or minimal residual disease, where the tumour load is con-
siderably lower and the immune system of the host less
compromised. This latter aspect is further supported by
studies in acute leukaemia, in which a marked defect of the
killing machinery against autologous blasts has been
documented at diagnosis and, to a further extent, at relapse,
while in the remission phase of the disease there is often a
restoration of the autologous killing capacity (Foa et al.,
1991c). In view of the potentially lowest tumour burden and
of the presence of circulating cytotoxic effectors in patients
who have undergone an autografting procedure (Reittie et
al., 1989; Higuchi et al., 1989), this clinical setting concep-
tually represents an optimal scenario for future protocols of
gene-mediated vaccinations. Finally, since tumour specific
antigens are being progressively recognised through more
sophisticated cloning technologies (Van Der Bruggen et al.,
1991; Chen et al., 1992), it is realistic to speculate that in the
near future more powerful and specific vectors containing
both a given tumour antigen and the IL2 gene may be
constructed and applied to the management of cancer
patients.
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